BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28905176)

  • 1. The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study.
    Lee KS; Koo KC; Chung BH
    Int Urol Nephrol; 2017 Dec; 49(12):2119-2125. PubMed ID: 28905176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.
    Thalgott M; Kron M; Brath JM; Ankerst DP; Thompson IM; Gschwend JE; Herkommer K
    World J Urol; 2018 Feb; 36(2):177-185. PubMed ID: 29164326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
    Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O
    Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy versus external-beam radiotherapy for localized prostate cancer: long-term effect on biochemical control-in search of the optimal treatment.
    González-San Segundo C; Herranz-Amo F; Alvarez-González A; Cuesta-Álvaro P; Gómez-Espi M; Paños-Fagundo E; Santos-Miranda JA
    Ann Surg Oncol; 2011 Oct; 18(10):2980-7. PubMed ID: 21431406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients aged more than 70 had higher risk of locally advanced prostate cancers and biochemical recurrence in Korea.
    Kim JK; Cho SY; Jeong CW; Lee SB; Ku JH; Hong SK; Byun SS; Kwak C; Him HH; Lee SE; Jeong H
    BJU Int; 2012 Aug; 110(4):505-9. PubMed ID: 22314007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of minimally invasive radical prostatectomy in prostate cancer patients with high prostate-specific antigen: feasibility and 1-year outcomes.
    Do M; Ragavan N; Dietel A; Liatsikos E; Anderson C; McNeill A; Stolzenburg JU
    Int J Urol; 2012 Oct; 19(10):923-7. PubMed ID: 22762411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
    Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
    Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of positive surgical margins after radical prostatectomy at a single institution: preoperative and pathologic factors, and the impact of surgeon variability and technique on incidence and location.
    Lallas CD; Fashola Y; Den RB; Gelpi-Hammerschmidt F; Calvaresi AE; McCue P; Birbe R; Gomella LG; Trabulsi EJ
    Can J Urol; 2014 Oct; 21(5):7479-86. PubMed ID: 25347375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients.
    Wang H; Fang K; Zhang J; Jiang Y; Wang G; Zhang H; Chen T; Shi X; Li Y; Duan F; Liu J
    Int Urol Nephrol; 2017 Aug; 49(8):1391-1398. PubMed ID: 28550473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.
    Imnadze M; Sjoberg DD; Vickers AJ
    Eur Urol; 2016 Jan; 69(1):143-8. PubMed ID: 25913389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.